Listen: A Tussle With a Rattlesnake Can Take a Bite Out of Your Wallet
Listen to 51Ƶ Health News' Jackie Fortiér recount how a backyard snakebite led to a harrowing hospitalization — and big bills — for a San Diego family.
Drug Costs
61-80 of 705 results
-
-
What’s at Stake: A Pivotal Election for Six Big Health Issues
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
-
PBM Math: Big Chains Are Paid $23.55 To Fill a Blood Pressure Rx. Small Drugstores? $1.51.
Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts. Georgia Republican Gov. Brian Kemp, though, vetoed a related bill that would have helped independent pharmacies, citing the unfunded cost of the move.
By Andy Miller -
Medicare Drug Plans Are Getting Better Next Year. Some Will Also Cost More.
Every year, Medicare officials encourage beneficiaries to shop around for their drug coverage. Few take the time. This year, it might be more important than ever.
By Susan Jaffe Yet Another Promise for Long-Term Care Coverage
Episode 367As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join 51Ƶ Health News’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a 51Ƶ lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
-
Employers Haven’t a Clue How Their Drug Benefits Are Managed
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
By Arthur Allen -
The Health of the Campaign
Episode 366The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join 51Ƶ Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews 51Ƶ Health News’ Lauren Sausser, who reported and wrote the latest 51Ƶ Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code.
-
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could’ve brought down prices of some prescription drugs, but it was blocked by the courts.
Congress Punts to a Looming Lame-Duck Session
Episode 365Congress left Washington for the campaign trail this week, but not before approving a spending bill that expires shortly before Christmas. Lawmakers will be busy after the election working on not just the legislation needed to keep the government running, but also several health programs set to expire. Meanwhile, Republicans continue to downplay abortion as Democrats press it as a campaign issue. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Joanne Kenen of Johns Hopkins University and Politico join 51Ƶ Health News chief Washington correspondent Julie Rovner to discuss these stories and more.
American Health Under Trump — Past, Present, and Future
Episode 364Dreaming of a Trump victory, Republicans have a wish list of health policy changes — including loosening Affordable Care Act regulations to make cheaper coverage available and ending Medicare drug price negotiations. Meanwhile, after a publicly reported death stemming from a state abortion ban, Vice President Kamala Harris is emphasizing the consequences of Trump’s work to overturn Roe v. Wade. Tami Luhby of CNN, Shefali Luthra of The 19th, and Joanne Kenen of Politico and Johns Hopkins University join 51Ƶ Health News senior editor Emmarie Huetteman to discuss these stories and more.
-
California May Regulate and Restrict Pharmaceutical Brokers
California lawmakers are moving to rein in the pharmaceutical middlemen they say drive up costs and limit consumers’ choices. The bill sent to Gov. Gavin Newsom would require pharmacy benefit managers to be licensed in California and would ban some business practices. Newsom vetoed a previous effort three years ago.
By Don Thompson -
-
Perspective
With TV Drug Ads, What You See Is Not Necessarily What You Get
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
-
For Pharma, Trump vs. Harris Is a Showdown Between Two Industry Foes
Vice President Kamala Harris is seen as more aggressive than former President Donald Trump in taking on pharmaceutical companies, but Trump allies say he would also make lowering drug costs a top priority.
-
New Lines of Attack Form Against the Affordable Care Act
While fighting potential fraud in government programs has long been a conservative rallying cry, recent criticisms of the Affordable Care Act represent a renewed line of attack on the program when repealing it is unlikely.
-
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
By Arthur Allen -
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
By Arthur Allen -
Harris, Once Biden’s Voice on Abortion, Would Take an Outspoken Approach to Health
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access — hitting former President Donald Trump on an issue that could undermine his chances of victory.
At GOP Convention, Health Policy Is Mostly MIA
Episode 356After an assassination attempt last weekend sent former President Donald Trump to the hospital with minor injuries, the Republican National Convention went off with little mention of health care issues. And Trump’s newly nominated vice presidential pick, Sen. J.D. Vance of Ohio, has barely staked out a record on health during his 18 months in office — aside from being strongly opposed to abortion. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Joanne Kenen of Johns Hopkins University and Politico Magazine join 51Ƶ Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews 51Ƶ Health News’ Renuka Rayasam, who wrote June’s installment of 51Ƶ Health News-NPR “Bill of the Month,” about a patient who walked into what he thought was an urgent care center and walked out with an emergency room bill.